Anivance AI, founded in December 2021, is a team of passionate engineers and scientists committed to developing innovative technologies and solutions that advance animal welfare and sustainability. The name "Anivance AI" is a portmanteau of the words "animal," "advance," and "AI," reflecting the team's mission to use artificial intelligence to make a positive impact on the world. The team has developed a modular design process that simplifies, enhances reliability, and reduces costs in chip design. Achieved over five-fold improvement in chip stability and performance, enhancing biological diversity and compatibility to create advanced microsystems.

Yang Ming Regenerative Medical Technologies Co. leverages advanced stem cell and exosome patent platforms from the Stem Cell Research Center of our university's School of Medicine. Centered on stem cells and exosomes, the company develops regenerative therapies targeting unmet medical needs, such as acute lung injury and liver diseases, in collaboration with hospitals through clinical trials and drug development of exosome-based regenerative products. Additionally, it plans to establish Taiwan’s first PIC/S GMP-compliant automated facility for large-scale production of stem cell and exosome biopharmaceuticals, creating a high-capacity, pharmaceutical-grade manufacturing base for regenerative medicine products.

Using human umbilical stem cells, Yang Ming StemMax provides the world's first patented cell therapy for effectively reversing and repairing pulmonary fibrosis that currently has no cure. The irreversible and progressive deterioration of pulmonary fibrosis causes respiratory failure and death. The US FDA approved anti-fibrosis drugs for lungs, Pirfenidone and Nintedanib, can only slow down the rate of fibrosis but cannot cure pulmonary fibrosis. The company founder, Dr. Yu-show Fu of NYCU medical school, has achieved using allogeneic (non-autologous) human umbilical Mesenchymal Stem Cells (hUMSCs) to reverse and repair pulmonary fibrosis, and obtained multiple patents for this innovation. The breakthrough cell therapy awakens the autologous regeneration mechanism and repairs scarred lung tissues in animal studies, increasing the Oxygen Saturation (SpO2) level in rats with bleomycin-induced pulmonary fibrosis from 80% to 93%. Experiments have proven that its safety, efficacy, and cost are superior to two existing anti-fibrosis drugs and adipose-derived Mesenchymal Stem Cells (AdMSCs), which can cause severe inflammations at treatment sites. Yang Ming StemMax’s human cell therapies are highly safe and non-tumorigenic. These cells retain stable stem cell properties even after twenty generations. There is no need to store one’s own umbilical cord, when in need, immediate treatment is available from our cell bank to effectively reverse and repair pulmonary fibrosis.

WiseRegen aims to develop and commercialize induced pluripotent stem cell (iPSC) technology, with the goal of becoming the first company in the Asia-Pacific region to use iPSC technology to develop various cell therapies.

The current main product: Interlocking intramedullary nail distal screw hole positioning device (iMET), which can solve the clinical unmet needs of IM Interlocking Nail's interlocking hole positioning for the clinical Unmet needs. iMET has obtained the US FDA 510(k) marketing authorization (K-163037), confirming the safety and efficacy of this innovative medical device.

AItewan BioMedical Technology Inc. was founded by Distinguished Professor Wu Yu-Te of National Yang Ming Chiao Tung University (NYCU), following the execution of two National Science and Technology Council (NSTC) Taiwan Germination Program I and II. These projects focused on the use of artificial intelligence to assist in the automatic annotation of brain tumor MRI images at multiple time points both pre- and post-operation, and on the development of the DeepBT intelligent precision medicine system for brain tumors: lesion detection and annotation over time (Tracker). The company was established with the approval of NYCU's spin-off regulations for AI-based smart healthcare startups, co-founded by Distinguished Professor Wu Yu-Te and Dr. Guo Wan-Yuo.
The brain tumor detection assistance system resulting from these NSTC research projects, known as the DeepBT Detector, has been exclusively licensed to NYCU and Taipei Veterans General Hospital. The DeepBT Detector has received multiple professional awards, including the "2022 Future Tech Award," the "19th National Innovation Award - Academic Research and Innovation Award," and the "National Innovation Advancement Award."
Our company's business philosophy emphasizes the full utilization of AI technology to enhance patient care quality, reduce the workload of physicians, and achieve the goals of fast, objective, quantitative, accurate, and seamless healthcare.
AItewan BioMedical Technology will continue to collaborate with medical institutions such as NYCU, Taipei Veterans General Hospital, Taichung Veterans General Hospital, Cheng Hsin General Hospital, Shin Kong Wu Huo-Shih Memorial Hospital, and the NYCU Affiliated Hospital. Additionally, the company will form strategic alliances with various information system vendors to assist in promoting and implementing AI technology.

Founded in 2016, Oenix Biotech is a collaborative effort backed by Accton Technology, Fu Hsun Investment, National Yang Ming Chiao Tung University, and Ofuna Tech.
We are dedicated to our philosophy of "TECHNOLOGY INNOVATION FOR HUMAN WELFARE." By leveraging Accton's IoT technology, we apply our solutions across various sectors, with a strong focus on the senior care market. In response to the challenges posed by an aging population, we harness Japan's expertise in elderly care to introduce specialized care food products aimed at enhancing the quality of life for middle-aged and elderly individuals in Taiwan. This commitment reflects our core mission of improving lives through innovative technology.

RGENE Biotech focuses on early-stage clinical development and the licensing of biopharmaceutical technologies, with the goal of becoming a pioneering leader in botanical new drugs and innovative medical devices.

Cubic Genomics is founded by core members from the Genomics Research Center at Yang Ming University, Taiwan’s first established genomics center. With independent teams specializing in sequencing, microarrays, and bioinformatics, the company brings nearly two decades of experience in genomic analysis services. Building on this expertise, Cubic Genomics has developed the Cubic Station as an optimized solution for genomic data analysis.

Amengine is a biomedical optoelectronics solution provider under the Ennostar Group. Its core technology is the integration of the parent company's optical modules and the circuit design and algorithms of Professor Paul C.-P. Chao’s team at National Yang Ming Chiao Tung University. Extending the core technology allows for the production of wireless patches for physiological monitoring, sports equipment, smart home, point-of-care testing (POCT), and other applications.

FaceHeart Corp. improves human health through its FDA 510 (k) cleared AI-driven, video-based contactless vital signs solution, FaceHeart Vitals™, providing a simple, comfortable, and cost-effective method to help patients manage their health. With only a single camera, our cutting-edge technology measures the following vital signs: Heart Rate (HR), Blood Pressure (BP), Respiration Rate (RR), Oxygen Saturation (SpO2), Heart Rate Variability (HRV), Atrial Fibrillation (AFib), and Stress Index. (1)150M Images from >5000 Patients (2)FDA 510(k) NO: K223622 (3)Medical-Grade Accuracy (4)Supports Web & Edge Solutions.